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DALYs, 14.6%). For the age group 65 and over, after adjusting for population, the
burden increases 7 fold. The 3 conditions, overall, represent 2,03 DALYs per 1000
Colombians in that age range. CONCLUSIONS: Despite the lower incidence of
pneumococcal disease in adults, as compared with children, its burden is still
significant, comparable, for example, to that of schizophrenia or epilepsy in Co-
lombia. This study may provide a benchmark for future preventive interventions
and for efficient resource allocation.
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OBJECTIVES: To review the changes in HIV in terms of course of the disease over
the past five years and its consequences, to assess whether existing economic
models in HIVwould need to be updated to account for these changes in case these
were used for the economic evaluation of new treatments in HIV. METHODS: A
systematic literature review was carried out in PubMed, using both MeSH and key
words, focusing on the following areas: opportunistic infections (OIs), health con-
sequences, costs, quality of life, adherence and compliance and efficacy of treat-
ments. In addition, current guidelines were identified and reviewed. For treat-
ments we focussed on maraviroc, etravirine and raltegravir. RESULTS: At total of
1787 hits were obtained from the above-mentioned strategy. Finally data on 341
articles extracted. For treatments, data from six trials on efficacy and adverse event
datawere extracted and used in ameta-analysis (not reported here). In terms of OIs
it was clear that fewer patients suffer from these infections compared to the early
2000s. Data on costs indicated that new costs were available by CD4 cell count.
There are substantial new data available on quality of life in HIV, however, with
several publications providing data by CD4-cell strata. Data on health conse-
quences showed that patients increasingly live long enough to suffer from LT
health consequences such as cardiovascular disease and cancer. Guidelines indi-
cated that treatment algorithms had changed markedly in the last five years and
that comparison to OBT is no longer an acceptable comparator strategy in eco-
nomic modelling. CONCLUSIONS: The management of HIV has changed substan-
tially since 2006. Patients live longer, are healthier and suffer from “common”
health consequences such a cardiovascular disease and cancer. Any health eco-
nomic model in this disease area should take these aspects into consideration.
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OBJECTIVES: When modeling the course of disease it is crucial to make proper
assumptions concerning transition probabilities between health states. Two dif-
ferent approaches may be adopted: constant or time-dependent probabilities (i.e.
survival curves). Most of published economic analyses of hepatitis C treatment are
based on models with constant probabilities. Using survival curves is more time-
consuming and complex butmay result inmore accurate estimates. Our aimwas to
compare the impact of both methods on results of chronic hepatitis C modeling.
METHODS: A Markov model was developed to describe hepatitis C patients flow.
Time horizon of 50 years was chosen, cycle length was 1 year. Health states distin-
guished in the model were: fibrosis, compensated cirrhosis (CC), decompensated
cirrhosis (DC), hepatocellular carcinoma (HCC), liver transplant (LT) and death. The
possible transitions were: fibrosis-CC, CC-DC, CC-HCC, DC-HCC, DC-LT
and from each state to death. Transition probabilities between health states were
estimated based on clinical trials evaluating the natural course of chronic hepatitis
C progression: either by calculating constant yearly rates or by using Weibull
curves estimated from reported Kaplan-Meier curves (the same data source for
each transition). Time spent in each of health states was compared between those
two approaches. RESULTS:The average time spent by a CC patient in states CC, DC,
HCC and LT was 18.3, 1.6, 0.3 and 1.3 years for constant probabilities, and 14.2, 3.2,
1.1 and 1.6 years for survival curves. Average survival was 21.5 and 20.2 years,
respectively. CONCLUSIONS:Method of calculation of transition probabilities may
have a significant impact on results of modeling, which may further influence
incremental cost-effectiveness ratios in economic analyses. The decision on the
method should bemade on the base of nature of events that are beingmodeled – for
some it may be more accurate to apply the survival curves approach.
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OBJECTIVES: To illustrate the application of an extended Cox regression model
with time-dependent treatment effects to real-world observational data.
METHODS: A retrospective US hospital database analysis was conducted among
adult invasive aspergillosis (IA) patients receiving their first antifungal therapy
during ICU stay. To assess the initial antifungal treatment effect on survival/LOS, a
survival analysiswas conductedwith event defined as “discharged alive”, censored
being “expired in hospital”, and time variable being treatment-initiation-to-dis-
charge (DITD). Key demographic, clinical and treatment variables were included.
Regimen A was the reference group and compared to regimen B (inactive against
IA, possibly indicating a treatment delay). Proportional hazard assumptions for the
treatment variable were assessed by the Schoenfeld residuals significance test.
When significant, treatment-by-time interaction together with its main effects
were included within an extended Cox model to account for the proportional haz-
ard violation. Multiple functional forms for time were considered in treatment-by-
time interactions. Due to the lack of direct SAS output for specific time points,
time-specific hazard ratios (HR) between treatments were manually calculated
incorporating bothmain effects and time covariates.RESULTS:A continuous linear
treatment-by-time interaction was constructed for Drug B since the null hypothe-
sis of Schoenfeld test was rejected. Consistent with an increasing time-interaction
effect (HR1.032, p0.0001), HR of drug B increased over time: Drug B patientswere
57% less likely (HR0.43, p.0001) to be discharged alive compared to Drug A at
mean switch time to other IA-active drugs (9 days), and 27% less likely (HR0.73,
p0.0297) to be discharged alive at mean DITD (25 days). Hazards would be equiv-
alent (HR1) at day 35, although by then most patients on regimen A (81%) had
switched/been discharged. CONCLUSIONS: The extended Coxmodel can be imple-
mented as an adjustment for the proportional hazard violation in observational
data analysis to obtain unbiased survival results.
PIN68
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OBJECTIVES: In retrospective claims-based studies of drug exposures and resultant
safety/tolerability issues (TIs), researchersmust define an a-priori “at-riskwindow”
– the time period in which observed TIs are classified as resulting from drug expo-
sure. In HIV, interruption of combination antiretroviral therapy (cART) may cause
detrimental clinical outcomes; thus, if a TI necessitates a switch in cART, the
claims-based evidence of healthcare utilization for TIs may persist even after
switching. This study quantified the impact of at-risk window assignment on ret-
rospectively-estimated incidence and costs of TIs.METHODS: Data were Medicaid
claims from 15 states. Subjects were HIV patients 18–64 years old initiating
atazanavir, darunavir, fosamprenavir, or lopinavir-based cART regimens from Jan-
uary 1, 2003 to July 1, 2010. Outcomes: incidence and costs of new-onsetmedically-
attended (ICD-9-CM-coded or treated) TIs (gastrointestinal, lipid abnormalities, di-
abetes/hyperglycemia, rash, jaundice) during a period of up-to 6 months post-
cART-initiation or censoring at switch. RESULTS: Sample included 20,024 patients;
mean age 42 years, 34% female, 48% black. When extending the at-risk window for
7 days post-switch, differences in incidence rates of TIs per 1,000 patient-months
were: gastrointestinal (76.1 with extension vs. 73.7 without); lipid abnormalities
(23.5 vs. 22.3); diabetes/hyperglycemia (9.0 vs. 8.8); rash (98.5 vs. 96.0); jaundice (0.59
vs. 0.57). When extending the cost-accrual window to include costs of TIs that
persist after switching, differences in the estimated per-patient per-month (PPPM)
costs of TIs were: gastrointestinal ($72 with extension vs. $75 without); lipid abnor-
malities ($27 vs. $22); diabetes/hyperglycemia ($71 vs. $67); rash ($7 vs. $8); jaundice
($0.4 vs. $2). CONCLUSIONS: Extension of at-risk windows increased estimated
incidence rates of TIs, decreased estimated PPPM costs of acute TIs (i.e., gastroin-
testinal, rash, jaundice) and increased the estimated PPPM cost of chronic TIs (i.e.,
lipid abnormalities, diabetes/hyperglycemia). These novel results may inform fu-
ture retrospective studies of TIs in cART.
SENSORY SYSTEMS DISORDERS – Clinical Outcomes Studies
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OBJECTIVES: Atopic dermatitis is a chronically relapsing inflammatory skin con-
dition accompanied by pruritus which, when severe, can negatively impact a pa-
tient’s quality of life. The objective of this study was to perform ameta-analysis of
randomized controlled trials (RCTs) of topical therapies compared against their
vehicles, and systemic therapies compared against their placebos, and to record
how these therapies changed the magnitude of pruritus associated with atopic
dermatitis. METHODS: Data for this meta-analysis were extracted from Medline,
Embase, and the Cochrane Controlled Clinical Trials Register, as well as follow-up
references in retrieved articles from years 1977 to 2011. Initial search of systemic
therapies in relieving the pruritus of atopic dermatitis yielded 205 studies. Out of
the 205 studies, 52 studiesmet the inclusion criteria, with 41 and 11 studies involv-
ing topical and systemic treatment of pruritus of atopic dermatitis, respectively.
Standard inverse variance fixed-effects meta-analysis was used to calculate the
pooled estimates for RCTs falling under each type of treatment. RESULTS: The 52
studies were analyzed using STATA SE version 10. Meta-analysis results showed
that overall, compared to systemic medication of atopic dermatitis, the topical
medications significantly reduced atopic pruritus by 35.3% (RR, 0.647; 95%CI, 0.619-
0.677). Among the topical medications, compared to the use of vehicle, the use of
anti-histamines, calcineurin inhibitors and topical corticosteroids as therapeutic
agents significantly reduced the pruritus of atopic dermatitis by 27%, 36% and 34%
in patients, respectively. CONCLUSIONS: The topical treatments were more suc-
cessful at reducing atopic pruritus compared to the systemic treatments. Overall,
calcineurin inhibitors were the most effective antipruritic agents. Verifiable pruri-
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tus reduction should be included as a primary or secondary endpoint in future
randomized clinical trials of investigative agents for atopic dermatitis.
PSS2
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OBJECTIVES: To evaluate the quality of published evidence of oral antibiotic and
isotretinoin therapies in the treatment of moderate to severe acne. METHODS: A
systematic search of published literature was conducted using PubMed and Em-
base using key word “acne” and therapy names doxycycline; tetracycline; minocy-
cline; erythromycin; sulfamethoxazole-trimethoprim (SMXTMP); azithromycin;
isotretinoin; and tretinoin. Studies evaluating topical retinoids and oral antimicro-
bials were also included. No date restrictions were used in order to capture all
relevant studies. Studies were eligible for inclusion if they meet the following cri-
teria: 1) randomized or observational clinical evaluations in humans; 2) published
in English; 3) duration of 8 week period or greater; and 4) evaluated at least 5
subjects. After title and abstract review, relevant citations were obtained and re-
viewed for inclusion. Data was abstracted into a standardized data collection form
by one author and verified by another. Study quality was rated using the Jadad
scale. RESULTS: A total of 588 articles were identified, but only 164 studies met all
inclusion criteria. The mean (SD) minimum age was 14.2 (2.32) and study duration
was 19 weeks (SD39). On average the sample size per treatment arm was 92
(SD176). Study designs included: crossover (6); observational (69); randomized-
controlled trial (82), non-randomized (1) and not reported/unknown (6). The num-
ber of studies evaluating the various treatments were: azithromycin (16); doxycy-
cline (24); erythromycin (20); isotretinoin (86); minocycline (40); SMXTMP (2); and
tetracycline (47). A total of 204 studies were RCTs, with 57 (28.1%) reporting inten-
tion-to-treat and 146 (71.9%) per-protocol results. Among RCTs, the mean (SD)
Jadad score was 2.75 (1.50) for azithromycin; 2.81 (1.76) for doxycycline; 4.00 (1.04)
for erythromycin; 2.80 (1.52) for isotretinoin; 3.32 (1.35) for minocycline; and 3.57
(1.02) for tetracycline. CONCLUSIONS: In general, the quality of randomized con-
trolled trials evaluating antibiotic treatments for moderate to severe acne is vari-
able.
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OBJECTIVES: In recent years, methodologies used in outcomes research have ad-
vanced. A tool to effectively communicate information through graphical means is
a necessity in a field where clinicians, epidemiologists, economists, and statisti-
cians interact frequently. Using data visualization techniques, we present treat-
ment patterns among patients with psoriasis. METHODS: Using 100% National
Medicare Data with Part D information for psoriasis patients over 65, who had at
least one diagnosis for psoriasis were selected for study. We identified patients
who initiated therapy with tumor necrosis factor (TNF) and non-TNF medications.
For 2 years after the initiation of biologics, we examined treatment patterns such as
switching to another TNF, a non TNF, and discontinuation. Using a processing
language, we created a data visualization tool to show how patients change their
treatment pattern after first, second and third switches. RESULTS: 2,208 psoriasis
patients initiated their therapy with a TNF agent. 7.47% switched to another TNF,
2.22% switched to a non-TNF, 53.35% discontinued their therapy and 36.96% con-
tinued their initial therapy. Among the patients who switched to another TNF,
49.70% stayed on the switched therapy, 29.70% discontinued, 20.00% switched to
another TNF and no patients switched to a non-TNF. In 2 years after TNF initiation,
6.06%of patientswhomade a second switch froman initial TNF, switched to a third
TNF. 69.70% continued their second switch, 24.24% discontinued their second TNF
and no patients switched to a non-TNF. CONCLUSIONS: Data visualization tools
can effectively help researchers visualize these complicated treatment patterns,
which can be difficult to present, especially if analyzed for subsequent years and
with various switching patterns.
SENSORY SYSTEMS DISORDERS – Cost Studies
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OBJECTIVES: To estimate the financial impact of adopting ustekinumab as an ad-
ditional psoriasis treatment option on a United States (US) health plan formulary,
while incorporating comparative evidence.METHODS: Themodel perspective was
a 1 million-member US health plan (including only direct healthcare costs). Psori-
asis prevalence and biologic penetration rates were derived from publically avail-
able US sources. Base case analysis examined increasing ustekinumab market
share from launch through 5 years, with commensurate decreases inmarket share
of other biologics. Treatment costs (adalimumab, etanercept, infliximab, and
ustekinumab) were computed using August 2011 wholesale acquisition costs and
US FDAprescribing information for induction/maintenance dosing. Responder and
non-responder cohorts were modeled based on disease response rates. Responder
cost inputs included drug acquisition/administration/monitoring/outpatient vis-
its. Non-responder cost inputs included supportive care/inpatient costs. No clini-
cally significant differences in rates of adverse events requiring treatment were
assumed. RESULTS: In each modeled year, 0.03% of the health plan population
would receive biologic treatment for moderate to severe psoriasis. Without usteki-
numab, total biologic drug budget in the base yearwas predicted to be $8.42million,
and total annual medical budget for moderate to severe psoriasis was estimated at
$9.80 million. By year 5, estimates increased by 4.7%. By adding ustekinumab,
estimated therapy budget increased by 6.3% and overall medical budget increased
by 3.7% over the course of 5 years. These estimates incorporated comparative data,
which predicted the number of disease responders increasing by 15% over the
same period. Net budget increase for all covered lives was estimated at $0.031 per
member per month by year 5. CONCLUSIONS:Model results indicated reimburse-
ment for ustekinumab may have minimal impact on a US health plan’s budget,
given the relatively small size of the eligible population. Additionally, by including
comparative evidence, results illustrated the estimated positive clinical impact of
adding ustekinumab to formulary.
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OBJECTIVES: Isotretinoin, medicine used to treat severe acne has been the subject
of various studies to investigate the relationship between therapy and psychiatric
disorders. At the same time, the demand has been growing this item in the Na-
tional Health System (SUS) which incorporated the drug since 2001 and its use is
standardized by the Clinical Protocol and Therapeutic Guidelines by SUS. The aim
of work was to quantitatively evaluate the demand Isotretinoin of in the year 2011
and the financial impact of this item in the total distributed in Component Special-
ized Pharmaceutical Services –CEAF (program for access to medicines under SUS)
METHODS: Survey demand data and distributed financial value of Isotretinoin 20
mg of 2011 in SIGAF-(Computerized Management of the State Pharmaceutical As-
sistance Minas Gerais) in relation to the total amount distributed to all items of
CEAF. RESULTS: In 2011, the demand of the Isotretinoinwas 9374 new patients, the
second-placed; iron hydroxide 100mg, 3111, budesonide formoterol 400/200mcg
was placed third with 2177. The total amount distributed was equivalent to 8715
million dollars, 8% of total expended with 196 medicines that make up the CEAF.
CONCLUSIONS: Isotretinoin was the most requested in 2011 in CEAF, three times
higher than the second and 4 times higher than the third. At the same time, spend-
ing on thismedicine is relevant, considering the percentage of the total spent on all
CEAF’smedications. This represents 11.6% of the total amount spent in the State of
Minas Gerais with the treatment of cardiovascular diseases, chronic diseasesmost
prevalent in Brazil according to WHO. Considering the known risks and the lack of
conclusive studies on other adverse effects of Isotretinoin, the results highlight the
need for closer monitoring of patients and control this medicine, in order to avoid
the rampant consumption and irrational.
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OBJECTIVES:Weight of glaucoma as a cause of blindness remains significant. Thus
the problem of drug supply of glaucoma patients is actual for health care system of
Russian Federation. We conducted 3 pharmacoeconomic studies for treatment of
open-angle glaucoma for each antiglaucoma drugs groups (eye-drops): prostaglan-
din analogues (Travatan (travoprost), Xalatan (latanoprost); carbonic anhydrase
inhibitors (CAI) (Azopt (brinzolamide), Dorzopt and Trusopt (dorzolamide)) and
combined drugs of prostoglandin analogues and beta-blocker (Duotrav
(travoprosttimolol) and Xalacom (latanoprosttimolol) to find optimal antiglau-
coma drugs from pharmacoeconomics perspective in Russia. METHODS: Cost-ef-
ficacy and budget impact analysis were used, direct costs were considered.
RESULTS: In the first studywe found that Travatan is dominant in comparisonwith
Xalatan and provide lower cost per effective glaucoma control per year per patient
– cost-efficacy ratio (CER) for Travatan was 18,092 RUB and for Xalatan 19,270 RUB.
Furthermore Travatan to Xalatan provided 1091 RUB cost saving per patient per
year. The second pharmacoeconomic study of CAIs has shown that Azopt had
benefits in terms of cost-efficacy analysis to Dorzopt and Trusopt: CER (cost of
achieving annual control for glaucoma by 1% patients) for Azopt it was 304 RUB, for
Dorzopt – 342 RUB, for Trusopt – 382 RUB. The third study has shown advantage of
Duotrav in comparison with Xalacom in terms of cost-efficacy analysis and budget
impact analysis. Duotrav had lower CER (cost per 1% of patients, for whom treat-
ment remains effective for 5 years) 1345 RUB in comparison with 1463 RUB for
Xalacom and provided 1721 RUB of cost-saving (discounted at 3%). CONCLUSIONS:
The results of conducted pharmacoeconomic studies show that Travatan, Azopt
and Duotrav are dominated drugs among alternatives in health care system of
Russian Federation for treatment of open-angle glaucoma from perspective of
pharmacoeconomic analysis.
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